- Home
- TVGN vs LXRX Comparison
TVGN vs LXRX Comparison
Compare TVGN & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- LXRX
- Stock Information
- Founded
- TVGN 2020
- LXRX 1995
- Country
- TVGN United States
- LXRX United States
- Employees
- TVGN N/A
- LXRX N/A
- Industry
- TVGN Blank Checks
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- LXRX Health Care
- Exchange
- TVGN Nasdaq
- LXRX Nasdaq
- Market Cap
- TVGN 193.1M
- LXRX 228.8M
- IPO Year
- TVGN N/A
- LXRX 2000
- Fundamental
- Price
- TVGN $1.20
- LXRX $0.75
- Analyst Decision
- TVGN Strong Buy
- LXRX Buy
- Analyst Count
- TVGN 1
- LXRX 4
- Target Price
- TVGN $10.00
- LXRX $3.67
- AVG Volume (30 Days)
- TVGN 817.5K
- LXRX 3.8M
- Earning Date
- TVGN 08-13-2025
- LXRX 07-31-2025
- Dividend Yield
- TVGN N/A
- LXRX N/A
- EPS Growth
- TVGN N/A
- LXRX N/A
- EPS
- TVGN N/A
- LXRX N/A
- Revenue
- TVGN N/A
- LXRX $31,213,000.00
- Revenue This Year
- TVGN N/A
- LXRX N/A
- Revenue Next Year
- TVGN N/A
- LXRX N/A
- P/E Ratio
- TVGN N/A
- LXRX N/A
- Revenue Growth
- TVGN N/A
- LXRX 1251.21
- 52 Week Low
- TVGN $0.26
- LXRX $0.28
- 52 Week High
- TVGN $3.09
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- TVGN 48.04
- LXRX 61.01
- Support Level
- TVGN $1.09
- LXRX $0.64
- Resistance Level
- TVGN $1.31
- LXRX $0.77
- Average True Range (ATR)
- TVGN 0.10
- LXRX 0.06
- MACD
- TVGN -0.02
- LXRX 0.00
- Stochastic Oscillator
- TVGN 26.19
- LXRX 76.47
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.